The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at ...

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...

At least 21 million adults in the U.S. have experienced depression. And, while oral antidepressant medications are a common treatment, they don't work for everyone. Now, the Food and Drug ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a major ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making it much cheaper for the estimated 30,000 Australians with ...

Are you experiencing depression, anxiety, PTSD/PTSI, ADHD, or OCD? We can help. Stella Mental Health Boston specializes in Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ...

TITUSVILLE, N.J., July 22, 2024 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) ...